Management said the new name, logo, website and branding elements ... that could have a better safety profile than Boehringer Ingelheim’s Ofev. As well as the IPF candidate, the merger gave ...
Ensure your gluten-free friends enjoy Valentine's Day with perfect presents. Check out our top gift ideas, from delicious ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
13 Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing ...
Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...
Boehringer Ingelheim says it is on track to launch ... R&D pipeline that it says is the best in its 139-year history. The company expects to start around 10 new phase 2 and 3 trials within the ...
DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new vision for the future, reflected in a new ...
DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback